<DOC>
	<DOC>NCT00500266</DOC>
	<brief_summary>To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.</brief_summary>
	<brief_title>Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>MAIN INCLUSION CRITERIA: Male or female aged 68 years or older Determined by medical history, physical examination, and clinical judgment to be eligible for the study Documented vaccination with 1 or more doses of pneumococcal vaccine at least 3 years before study enrollment MAIN EXCLUSION CRITERIA: Known history of severe reaction to a vaccine Documented S pneumoniae infection within the past 5 years. Known or suspected immunodeficiency or receiving treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease requiring supplemental oxygen, endstage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator's opinion precludes the subject from participating in the study.</criteria>
	<gender>All</gender>
	<minimum_age>68 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>vaccine</keyword>
</DOC>